Filing identity and reporting period
The supplied filing is IsoRay, Inc.’s Form 10-K for the fiscal year ended June 30, 2017—not a 2016 Q4 filing for Perspective Therapeutics, Inc. The company reported as IsoRay and focused on Cesium-131 brachytherapy products. Investors should confirm the issuer and period before relying on this summary.
Business context and financial results
IsoRay develops, manufactures, and sells Cesium-131 cancer-treatment products. Prostate treatment remained its core market; the company said it generated 88% of fiscal 2017 product sales. The company operated as one reportable segment.
| Metric | FY2017 | FY2016 |
|---|---|---|
| Net product sales | $4.761 million | $4.769 million |
| Gross profit / margin | $0.838 million / 17.6% | $0.129 million / 2.7% |
| Operating expenses | $7.145 million | $5.211 million |
| Operating loss | $6.307 million | $5.082 million |
| Net loss | $6.162 million | $4.711 million |
| Net loss per share | $0.11 | $0.09 |
| Cash used in operating activities | $5.712 million | $3.884 million |
Revenue was essentially flat year over year. Gross margin improved substantially as cost of product sales fell 15%, but higher research and development and sales and marketing spending contributed to a larger operating and net loss. The annual report gives no clear consolidated gross-margin percentage; percentages above are calculated from reported sales and gross profit.
Liquidity, balance sheet, and cash flow
At June 30, 2017, cash and cash equivalents were $5.932 million, current certificates of deposit were $3.039 million, and working capital was $9.185 million, down from $12.536 million. The current ratio was 9.30, versus 12.47. Total assets were $12.269 million and shareholders’ equity was $10.602 million, compared with $18.102 million and $16.401 million, respectively, a year earlier. Total liabilities were $1.667 million; the balance sheet reported no conventional debt. Long-term obligations included a $0.561 million asset retirement obligation. Cash and cash equivalents declined $4.207 million during the year.
Material changes, outlook, and risks
- Growth spending and outlook: Management targeted 20% revenue growth in fiscal 2018 and estimated cash-flow break-even in three to five years if growth targets were achieved and no extraordinary costs arose. These are expectations, not guarantees. Management forecast cash and certificates of deposit would cover projected operating needs for the coming year, but also said it might need to raise capital within nine to twelve months to maintain its NYSE MKT listing. Potential financing could dilute shareholders.
- Planned investment: The company expected to spend about $250,000 in fiscal 2018 on production automation. A proposed new facility depended on acceptable financing; no assurance of financing or construction was given.
- Product and market concentration: Other brachytherapy sales fell 11% to $588,000, while prostate sales rose 2% to $4.173 million. Three customers accounted for approximately 37.6% of sales. The filing identifies competition, reduced prostate screening and active surveillance as risks to procedure volumes.
- Supply exposure: Approximately 85% of fiscal 2017 Cesium-131 supply came from a Russian supplier. Planned reactor outages and contract renewal created supply risks. The company described arrangements intended to broaden supply, including increased domestic supply and a Russian consignment arrangement, but their effectiveness was not assured.
- Regulatory and reimbursement risks: GammaTile’s FDA clearance remained pending after FDA requested additional information; management planned further testing and a filing by the third quarter of fiscal 2018. The associated Medicare add-on payment application was not under consideration pending FDA clearance. Inpatient reimbursement and future CMS payment levels remained uncertain.
- Unusual items and legal matters: A $48,000 gain from a revised asset retirement obligation estimate reduced fiscal 2017 expense; fiscal 2016 included a $456,000 gain. The company discontinued GliaSite in March 2016. A securities class action settled for $3.538 million, paid by insurers; a separate equity-plan class action settled for $195,000 and was dismissed in July 2017. A derivative lawsuit remained pending at the filing date.
The independent auditor issued an unqualified opinion on the consolidated financial statements. Management stated that disclosure controls and internal control over financial reporting were effective as of June 30, 2017.
Important facts for investors to verify
- Confirm the filing belongs to the intended issuer: this document names IsoRay, Inc., not Perspective Therapeutics, Inc., and covers the fiscal year ended June 30, 2017.
- Check subsequent financing, exchange-listing status, and cash runway against the company’s latest filings.
- Track actual fiscal 2018 revenue growth, operating cash burn, and progress toward management’s break-even outlook.
- Verify continuity, pricing, and realized volumes from Russian and domestic Cesium-131 suppliers.
- Review FDA progress and reimbursement developments for GammaTile, as well as customer concentration and the status of the derivative litigation.